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AUDIT
Our experience of treating adult bone lymphoma, A retrospective cross-sectional
study in a tertiary care center, Aga Khan University Hospital, Karachi
Masood Umer, Muhammad Younus Khan Durrani, Javeria Saeed, Nasir Uddin

Abstract
Objective: To determine the experience at the Aga Khan University Hospital in diagnosing and treating adult
patients with primary lymphoma of bone.
Methodology: All patients with Primary lymphoma of bone (PLB) that were diagnosed and/or treated at Aga Khan
University Hospital, Karachi from 2005 to 2019 were included as part of this study.
Result: There were 17 patients with PLB including 13 (76.5%) males and 4 (23.5%) females with a mean age of 44 ±
16.5 years. Nine patients were between 30-59 years of age at diagnosis. The mean follow-up time of patients was
80±46.7 months. Six patients had tumours of pelvic bone followed by tibia (5) and femur (4). Four patients had a
pathological fracture at the time of presentation whereas 2 (11.8%) required surgical fixation of the pathological
fracture. The stage of the tumour was based on Ann Arbor classification. Nine (52.9%) cases had Stage 1 disease, 7
(41.2%) had stage IV disease with metastasis in extra nodal tissues. As for treatment, every patient received
chemotherapy whereas 5 (29.4%) received adjuvant radiotherapy. Complete remission in the size of the tumour was
seen in 11 (64.7%) patients while 6 (35.3%) had partial remission. Post-treatment, 4 (23.5%) patients expired. The
mean Overall Survival (OS) time was 80.18 ± 46.71months with a survival rate of 76.5%
Conclusion: Primary lymphoma of the bone can be treated with medical regime and good prophylactic surgeries
to avoid pathological fracture such as intramedullary nailing.
Keywords: Lymphoma, Pelvic bone, Pathological fracture, Survival, Metastasis. (JPMA 71: S-83 [Suppl. 5]; 2021)

Introduction

pattern, or near normal which makes biopsy important.4,6

According to the WHO classification, primary lymphoma
of the bone (PLB) is defined as a monostotic disease
involving a single skeletal site with or without the
involvement of the regional lymph nodes, or as a
polyostotic disease affecting multiple skeletal sites
without visceral or lymph node involvement.1 Primary
lymphoma bone (PLB) is extremely rare. The diagnosis is
based on cortical and adjacent soft tissue involvement.
On the contrary distant visceral and lymph node
involvement is part of PLB or not is controversial in the
literature. PLB affects 1.7/1,000,000 people in US with 5%
of extra nodal involvement and 3% malignancies.2,3 It is a
tumour of lymphoid tissues as lymph nodes and spleen.4
It presents with pain or swelling of the affected area. The
tumour can be low grade, intermediate or high grade.
Burkett's lymphoma is an example of a fast-growing
tumour.4 PLB contributes to only 3% of all bone tumours
and is usually seen in adult life. It can occur in all bones
but predominantly in bones with marrow and most are
large cells with B cell lineage, called diffuse large B-cell
lymphoma (DLBCL).4,5 On plain x-ray, it can present with
the lytic pattern, sclerotic pattern, increased density

Due to the low prevalence even in countries with good
record maintainence as the United States, the information
on PLB is scarce. This study aimed to determine the
experience in diagnosing and treating adult patients with
PLB in a tertiary care hospital of Karachi. The paediatric
population was excluded because PLB in children is
treated as a systemic disease rather than an isolated bone
pathology.

Aga Khan University Hospital, Karachi, Pakistan.
Correspondence: Javeria Saeed. Email: javeria.saeed@aku.edu

Methods
A retrospective cross sectional study was conducted on all
patients diagnosed with PLB or treated at AKU from 2005
to 2019. The diagnosis was based on a biopsy of the bone
tumour. Patients were included in this study regardless of
sex, race, age and co-morbids. Moreover, patients who
had primary lymphoma other than bone or had received
treatment for a Secondary Lymphoma of bone were
excluded.
Approval for the study was obtained from the Ethical
Review Committee of the institution. Patients who were
part of the study were identified using medical record
numbers. Noted were demographics of the patients
including their age, sex, site of tumour, Follow-up (in
months), Co-morbids, Type of Lymphoma, Histological
subtype of Lymphoma, size of the primary tumour, stage
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of cancer, involved bone, presence of extra-lymphatic
spread, pathological fracture, modality of treatment
including Chemotherapy, Radiotherapy, Immunotherapy
and surgery, type of remission, number of relapses, size of
tumour after treatment (in case of incomplete remission)
and post-chemotherapy complications. The collected
data was analysed using Statistical Package for Social
Sciences v. 21 (SPSS). Means and frequency were
calculated along with survival analysis using the KaplanMeier test.

Results
Medical records of 17 patients with PLB were reviewed.
There were 13 (76.5%) males and 4 (23.5%) females with a
mean age of 44±16.5 years. Out of which 4 (23.5%)
patients were less than 30 years of age, 9 (53%) patients
were between 30-59 years and 4 (23.5%) were equal to or
above 60 years of age at diagnosis. The mean follow-up
time was 80±46.7 (8-184) months.
Some patients had comorbids along with the tumour in
which 2 (11.8%) patients had Diabetes Mellitus type 2 and 2
had hypertension. Hepatitis B, Gilberts syndrome, and
ischaemic heart disease were seen in only 1 (5.9%) case each.
All the patients had non-Hodgkin lymphoma DLBCL type.
Most of the patients had a tumour in the Pelvic bones
followed by the femur, tibia, radius, and scapula (Figure-1).
Lesion on kidneys on PET- CT was seen in 3 (17.6%) cases,

Figure-2: Overall survival curve of patients.

2 (11.8%) had a lesion in the liver on PET CT, 3 (17.6%)
presented with distant metastasis, and the remaining 9
(52.9%) had solitary bone lesions with no skipped or
distant lesions on PET CT. Pathological fractures were
noted in 4 (23.5%) cases at the site of the lesion. Surgical
fixation of the pathological fracture was required in only 2
(11.8%) patients.
The staging of the tumour was based on Ann Arbor
classification7 Stage 1 disease was seen in 9 (52.9%)
patients; 7 patients (41.2%) had stage IV disease with
metastasis in extranodal tissues. One (5.9%) patient had
stage II disease. As for treatment, every patient received
chemotherapy: 16(94.1%) received RCHOP (Rituximab,
Cyclophosphamide, Doxorubicin, Vincristine, and
Prednisolone), 3 (17.6%) received a high dose
(Methotrexate) MTX along with RCHOP regime, 1 (5.9%)
was given RDHAP (Rituximab, Dexamethasone,
cytarabine, and Cisplatin). Five (29.4%) patients returned
with febrile neutropenia for which chemotherapy was
stopped and treatment was given. One (5.9%) patient
each presented with acute gastroenteritis and oral
thrush whereas 10(58.8%) patients tolerated
chemotherapy well.
Five (29.4%) patients received radiotherapy. Complete
remission in the size of the tumour was observed in 11
(64.7%) patients with 6 (35.3%) having partial remission.
Multiple relapses in the course of treatment were
encountered in 4(23.5%) patients. Out of 17 patients, 4
(23.5%) expired, making the overall survival rate of
76.5% with a median time of 144.6 months (SEM 16.70)
(Figure-2).

Figure-1: Bone tumor sites in patients of Bone lymphoma.
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Discussion
Primary bone lymphoma (PLB) is extremely rare presenting
with pain and swelling on the affected area.2 The current
study was carried out to share our experience of patients
with PLB on their diagnosis and treatment. To our
knowledge, this is the largest study done in the
subcontinent (Pakistan, India, and Bangladesh) which
discusses the patients with the disease and their prognosis.
Even the Surveillance, Epidemiology, and End Results (SEER)
database of the US does not include the data regarding the
effect of chemotherapy on these patients.2 The principle to
treat PLB is far different from sarcomas.3 In recent times
much progress has been made to diagnose and stage the
disease by using PET CT. This provides the anatomical and
physiologic activities of the lesion. But still, no significant
change in the incidence and overall survival has been noted.
This supports the need to prospectively conduct a study at
a multicenter and multinational level.2,5 Jacob et.al, also
commented on the fact that appendicular tumour site is a
predictor of survival compared to axial locations but some
studies (which they describe in their publication) have
different observations due to confounding factors.2
Differential diagnoses of such lesions include Ewing's
sarcoma and osteosarcoma.3,4 According to the literature,
PLB occurs most commonly in the femur followed by the
pelvis. On the contrary in Japan, pelvis is the most common
site. PLB shows a variety of presentations on plain X-ray. The
X-ray of a patient of our series, who presented with a lesion
in the right sacroiliac joint, showed patchy increased density
along the right sacroiliac joint (Figure-3). In our study also,

Figure-3: X-ray Pelvis of our patient showing Patchy increased density noted along the
right sacroiliac joint.
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most of the cases were of pelvic bone followed by tibia
and femur. In PLB patients mostly present with pain (8095%), swelling in 30-40%, and pathological fracture in 1015%.9,10 The time between the disease onset and
presentation to the clinic is generally short (8 months).8
Also, lymphoma in bones can develop around prosthetic
devices especially anaplastic large cell lymphomas (ALCL)
which present with swelling and erythema at the surgical
site a few years after implant surgery.10 According to the
literature, the median age of diagnosis of PLB is 45-60
years while our patients mean age was 44 years which is
consistent with international data. For this reason
patients presenting with pain or swelling should be
advised plain X-ray to detect the lesion. In case a lesion is
noted, MRI should be performed which is the gold
standard for diagnosis of PLB. If PLB is in the bone with
local extension of the lesion, PET CT is recommended for
staging.5,8,11 In MRI more specific characteristics of PLB are
present as compared to the plain X-ray film.6 For staging
Ann Arbour system7 is used. Furthermore, metastatic
workup and biopsy are done to know the nature of the
disease and exclude other differentials, some studies
suggest doing anchored multiplex PCR. Seven patients in
the presented series showed metastatic disease. Bone
tumours cannot be dealt with under the care of a single
specialty. A multidisciplinary approach is recommended
and at our center, such cases are discussed in Tumour
Boards where orthopaedic oncological surgeons, medical
and radio-oncologist specialists offer their expert opinion
for the various treatment choices. The factors under
consideration include age, socioeconomic factors, and
marital status. Age is an important predictor of survival
which could be due to the ability to endure
chemotherapy and lesser comorbidities play a significant
role in giving treatment options to the patients. Higher
socioeconomic and married patients also show a better
prognosis when compared to their counterparts.2 The first
choice and evidence based treatment for DLBCL is
cyclophosphamide, doxorubicin, vincristine, and
prednisone (CHOP) plus etoposide. This has shown
complete remission. Immunotherapy with rituximab (RCHOP) is not well established in literature because most of
the data is from the time when rituximab was not
available in the market.4,6 Similarly, offering radiotherapy
is controversial and can be on case based need, still
further clinical trials are needed to prove its efficacy.8 It is
also recommended that immunotherapy should be given
before radiotherapy and currently R-CHOP is the first line
treatment for PLB.11 If PLB is in a weight bearing bone
then weight bearing limitations should be placed or the
patient should be in protected weight bearing to prevent
a fracture. At our institute the patients are discussed in
Vol. 71, No. 8 (Suppl. 5), August 2021
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tumour boards and the board decides on case need basis
that whether patient needs radiotherapy or not. On the
contrary, in a study patients with advanced-stage disease,
who were treated with chemotherapy plus radiotherapy,
had a poorer outcome compared with those who were
treated with chemotherapy alone. Post treatment once
remission is achieved, strict follow-up is required.
Literature has reported a local relapse of 7-10% and 1722% of distant metastasis.11

Conclusion
This study proves that PLB can be treated without any
surgical intervention. Primary lymphoma of bone can be
treated with good medical management. Prophylactic
surgery is done to avoid pathological fracture for example
intramedullary nailing in the femur. In this situation
surgical morbidity can be avoided by early diagnosis and
a multidisciplinary approach. Chemotherapy and if
needed radiotherapy is applied.
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